Anthrax Protective Antigen

Recombinant, Bacillus anthracis anthrax protective antigen expressed in a special strain of B. anthracis. One of three protein components of anthrax toxin produced by the pathogenic bacterium, Bacillus anthracis. Central moiety that mediates entry of lethal factor (LF) and edema factor (EF) into the target cell. PA83 binds to the cell surface via a type I membrane receptor with a von Willebrand factor A domain, known as anthrax toxin receptor. PA83 is proteolytically activated in vivo by a furin-like protease to produce a 63 kDa protein (PA63). PA63 self-associates to form a heptameric, cation-selective, voltage-gated, membrane channel that subsequently binds to LF and/or EF. Cleavage of the 20 kDa fragment from PA83 is necessary for binding of protective antigen to LF and EF.

Cell permeable: no

Primary Target
Type I membrane protein with a von Willebrand factor A domain called anthrax toxin receptor

Product does not compete with ATP.

Reversible: no

yes

Lyophilized from 50 mM NaCl, 5 mM HEPES, pH 7.5.

Following reconstitution aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 6 months at -20°C.

Reconstitute in 100 µl sterile, distilled H₂O to yield a final concentration of 1 mg/ml.

Single major band by SDS-PAGE. Several smaller minor components are apparent that may represent cleavage fragments of the PA.

Mogridge, J., et al. 2002. Biochemistry41, 1079.
Nassi, S., et al. 2002. Biochemistry41, 1445.
Ahuja, N., et al. 2001. Biochem. Biophys. Res. Commun.286, 6.
Bradley, K.A., et al. 2001. Nature414, 225.
Brossier, F., and Mock, M. 2001. Toxicon39, 1747.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)